Skip to main content

Market Overview

Oxford BioMedica To Manufacture More Doses Of AstraZeneca's COVID-19 Vaccine, Upgrades 2021 Outlook

Share:
Oxford BioMedica To Manufacture More Doses Of AstraZeneca's COVID-19 Vaccine, Upgrades 2021 Outlook
  • Oxford BioMedica Plc (OTC: OXBDF) has raised its forecast for cumulative revenues from AstraZeneca Plc (NASDAQ: AZN) by the end of 2021 to more than £100 million from £50 million pounds earlier.
  • The company did not provide any other details on its deal.
  • Oxford BioMedica also expects significant growth in Group Operating EBITDA in the year ending 2021.
  • AstraZeneca will purchase additional batches of Oxford BioMedica's COVID-19 vaccine in the second half of 2021, after successfully manufacturing large-scale batches of AstraZeneca's vaccine.
  • Oxford BioMedica announced an 18 month supply agreement in September 2020 under a three-year supply and development agreement with AstraZeneca for large-scale commercial manufacture of the adenovirus vector-based COVID-19 vaccine, AZD1222.
  • Price Action: AZN shares are up 0.57% at $56.20, and OXBDF shares are up 10.6% at $15.75 on the last check Tuesday.
 

Related Articles (AZN + OXBDF)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Guidance Health Care Offerings Small Cap Movers

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com